Colorectal cancer, the abnormal growth of cancerous cells in the large intestine or the rectum, is one of the most common ...

German biotech BioNTech today announced that the US Food and Drug Administration (FDA) has granted fast track designation to ...

US Oncologists anticipate rapid biosimilar uptake – up to 50% of PD-1/PD-L1 eligible patients within the first year – while ...

Solnerstotug showed a 14% response rate and 62% disease control in PD-L1 resistant tumors, surpassing typical expectations. Significant responses were observed in Merkel cell carcinoma and ...

PD-1 and PD-L1 inhibitors are types of immune checkpoint inhibitors, which are immunotherapy medications for treating cancer. Immunotherapy helps the immune system find and kill cancer cells. Some ...

January 15, 2026) - Nanjing Leads Biolabs Co., Ltd. (HKE: 9887) ("Leads Biolabs" or the "Company") today announced that Opamtistomig (LBL-024), its core investigational PD-L1/4-1BB bispecific antibody ...

The results of a preclinical study have identified a biological mechanism that explains why some patients don’t respond to immune checkpoint blockade (ICB) therapy for solid cancer tumors. The study, ...

The FDA's Fast Track designation helps to accelerate the development and review of products for serious and life-threatening conditions.